SCHEMBL3408510

SCHEMBL3408510

Nc1nc(-c2ccccc2)nc2[nH]nc(Nc3cccc(F)c3)c12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 9/20 0.56
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
HPGD P15428 1/20 0.49
GSK3A P49840 1/20 0.49
GSK3B P49841 1/20 0.49
ABCC1 P33527 1/20 0.49
FADS1 O60427 1/20 0.49
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
DPP4 P27487 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3409100 0.90 ABCG2 (0.45) ABCG2ALDH1A1LMNAPOLBHPGD
SCHEMBL3602136 0.88 ABCG2 (0.47) ABCG2ALDH1A1LMNAPOLBHPGD
SCHEMBL3413002 0.87 ABCG2 (0.54) ABCG2ALDH1A1LMNAHPGDKMT2A
SCHEMBL29648256 0.86 LMNA (0.48) ABCG2LMNAHPGDGRM4
SCHEMBL16492396 0.86 ABCG2 (0.55) ABCG2ABCC1FADS1DPP4KDM4E
SCHEMBL3592180 0.86 MAPT (0.55) ABCG2LMNAHPGDKMT2AL3MBTL1
SCHEMBL14861582 0.86 LMNA (0.48) ABCG2LMNAHPGDGRM4
SCHEMBL16492388 0.83 ABCG2 (0.57) ABCG2ABCC1KMT2ADPP4MEN1
SCHEMBL16140867 0.82 ABCG2 (0.60) ABCG2GRM4
SCHEMBL3408507 0.81 ABL1 (0.54) ABCG2ALDH1A1LMNAPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962634-B2 4-amino-3-arylamino-6-arylpyrazolo[3,4-d) pyrimidine derivatives, methods for their preparation and their use as antiviral agents DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2015-02-24 US claimed
EP-2049540-B1 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS DRITTE PATENTPORTFOLIO BETEILI (DE) 2010-12-22 EP claimed
EP-2049540-A1 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co.KG (DE) 2009-04-22 EP claimed
WO-2007147401-A1 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO.KG (DE) 2007-12-27 WO claimed
EP-2766367-B1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for the treatment of viral infections, in particular picornavirus infections SCANDION ONCOLOGY AS (DK) 2022-05-18 EP disclosed
US-9790225-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2017-10-17 US disclosed
US-9790225-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2017-10-17 US disclosed
US-9790225-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2017-10-17 US disclosed
US-8962634-B2 4-amino-3-arylamino-6-arylpyrazolo[3,4-d) pyrimidine derivatives, methods for their preparation and their use as antiviral agents DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2015-02-24 US disclosed
US-20140296259-A1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2014-10-02 US disclosed
US-20140296259-A1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2014-10-02 US disclosed
US-20140296259-A1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2014-10-02 US disclosed
EP-2766367-A1 4-AMINO-3-PHENYLAMINO-6-PHENYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS ANTIVIRAL ACTIVE SUBSTANCES Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG (DE) 2014-08-20 EP disclosed
WO-2013053942-A1 4-AMINO-3-PHENYLAMINO-6-PHENYLPYRAZOLO[3,4-D] PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS ANTIVIRAL ACTIVE SUBSTANCES DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2013-04-18 WO disclosed
EP-2049540-B1 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS DRITTE PATENTPORTFOLIO BETEILI (DE) 2010-12-22 EP disclosed
US-20100010018-A1 4-Amino-3-Arylamino-6-Arylpyrazolo[3,4-D) Pyrimidine Derivatives, Methods for their Preparation and their Use as Antiviral Agents DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2010-01-14 US disclosed
EP-2049540-A1 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co.KG (DE) 2009-04-22 EP disclosed
WO-2007147401-A1 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO.KG (DE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296259-A1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances POLL, RPP30, EIF2AK2 ABCG2 1780/4885ALDH1A1 1348/4885LMNA 1817/4885
US-20100010018-A1 4-Amino-3-Arylamino-6-Arylpyrazolo[3,4-D) Pyrimidine Derivatives, Methods for their Preparation and their Use as Antiviral Agents PNP, TYMP, EIF2AK2 ABCG2 136/4885ALDH1A1 1623/4885LMNA 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.